ANIP News and Press, ANI Pharmaceuticals Inc. From 03/09/23

Fourth Quarter and Full Year 2022 Financial Results -- Q4 net revenues of $94.2 million, net loss available to common shareholders of $(4.7) million and diluted GAAP loss per share of $(0.28) – -- Q4 Adjusted non-GAAP EBITDA of $23.3 million and adjusted non-GAAP diluted ...

2023-03-08 13:03:50 ET ANI Pharmaceuticals ( NASDAQ: ANIP ) is scheduled to announce Q4 earnings results on Thursday, March 9th, before market open. The consensus EPS Estimate is $0.67 (+24.1% Y/Y) and the consensus Revenue Estimate is $86.14M (+41.4% Y/Y). Over the la...

2023-03-08 10:27:33 ET Major earning expected before the bell on Thursday include: Arrival ( ARVL ) FuelCell Energy ( FCEL ) JD.com ( JD ) Paysafe ( PSFE ) Village Farms International ( VFF ) For further details see: Notable earnings befor...

ANI Pharmaceuticals ( NASDAQ: ANIP ) gained ~3% in the morning hours Wednesday, marking the biggest intraday gain since late January, after Guggenheim launched its coverage with a Buy recommendation citing the company’s hormonal autoimmune therapy Cortrophin Gel. Cortrophin...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, prior to market open. Nikhil Lalwani, President and Chief Executive O...

Summary Results from three major testosterone trials expected in 2023, including the largest testosterone cardiovascular safety/efficacy trials for men and women. AbbVie led Androgel 1.62% 5,246-participant cardiovascular safety trial is also measuring efficacy for dysthymia, clinical f...

ANI Pharmaceuticals ( NASDAQ: ANIP ) on Monday said it had got U.S. Food and Drug Administration (FDA) approval for its generic version of the drug carnitor. The FDA approval was for ANIP's levocarnitine tablets, 330 mg. ANIP's levocarnitine tablets are a generic version of the dr...

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets USP, 330 mg. ANI’s Levocarnitine Tablets are the generic version of ...

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral Solution, USP 20 mg/5 mL. ANI&...

ANI Pharmaceuticals ( NASDAQ: ANIP ) said the U.S. Food and Drug Administration (FDA) approved its generic antibiotic trimethoprim tablets USP, 100 mg. Trimethoprim is an antibiotic used to treat bacterial infections. "As we continue to focus on bringing niche...